Samuel M. Cohen, M.D., Ph.D.

Department Affiliations
Havlik-Wall Professor of Oncology

Chemical Carcinogenesis, Toxicology and Risk Assessment, Surgical Pathology, Urologic Pathology
For full details of Dr. Cohen's research, please visit his lab's webpage.

Education and Training
B.S. (Honors) University of Wisconsin, 1967
M.D., Ph.D. (Experimental Oncology) University of Wisconsin, 1972
Residency, St. Vincent Hospital, Worcester, MA, 1972-1975
Board Certified in Anatomic and Clinical Pathology, 1976

Teaching Activities
Medical Students: Small group discussions and laboratories
Graduate students: Advisor, supervisory committees
Residents: Surgical pathology, conferences
Director of Pathology Residency Program

National Activities
Editorial Board or Associate Editor: Fd. Chem. Toxicol., Int. J. Oncology, Urologic Oncology, Toxicol. Pathol., Pathol. Intl., Crit. Rev. Toxicol., Toxicology, J. Toxicol.
Advisory Panels:
Int. Life Sci. Inst. (ILSI) - Health and Environmental Sciences Institute Board of Trustees (HESI), 2001-present; Chairman, 2006-2008
International Life Sciences Institute Board of Trustees, 2007- present, Vice Chairman, 2010-2012.
National Instititute for Environmental Health Sciences (NIEHS)Board of Scientific Counselors, 2008-present
WHO-IPCS; Expert Panel on Carcinogens, 1999-2006
Expert Panel of the Flavors and Extracts Manufacturers Association, 2002-present
Numerous committees & panels with NIH, EPA, FDA, WHO, IARC, IPCS, national and international scientific organizations.

Notable Publications
Cohen, S.M. An enhanced thirteen-week bioassay as an alternative to screening for carcinogenesis factors. Asian Pac. J. Cancer Prev., 10 (DIMS Suppl.): 13-15, 2010.

Suzuki, S., Arnold, L.L., Pennington, K.L., Kakiuchi-Kiyota, S., Wei, M., Wanibuchi, H., and Cohen, S.M. Effect of pioglitazone, a peroxisome proliferator- activated receptor gamma agonist, on urine and urothelium of the rat. Toxicol. Sci., 113:349-357, 2010.

Suzuki, S., Arnold, L.L., Pennington, K.L., Chen,B., Naranmandura, H., Le, X.C., and Cohen, S.M. The dose effects of dietary administration of sodium arsenite on the urinary concentrations of arsenicals, including thio-metabolites, and on the urinary bladder epithelium. Toxicol. Appl. Pharm., 244:99-105, 2010.

Cohen, S.M. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: The two year bioassay is no longer necessary. Toxicol. Pathol., 38:487-501, 2010.

Zlotta, A.R., Cohen, S.M., Dinney, C., Droller, M., van der Kwast., T.H., van Rhizjn, B.W.G., Bochner, B., Ameil, G., and Jewett, M.A.S. Overview of risks for and causes of bladder cancer. Urol. Oncol., 28:329-333, 2010,

Yokohira, M., Arnold, L.L., Pennington, K.L., Suzuki, S., Kakiuchi-Kiyota, S., Herbin-Davis, K., Thomas, D.J., and Cohen, S.M. Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (+3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol. Appl. Pharm., 246:1-7, 2010.

Cohen, S.M. An enhanced 13-week bioassay: An alternative to the 2 year bioassay to screen for human carcinogenesis. Exp. Toxicol. Pathol., 11:15-17, 2010.

Cohen, S.M., Gordon, E.B., Singh, P., Arce, G.T., and Nyska, A. Folpet’s carcinogenic mode of action in mice and evaluation of its relevance to humans. Crit. Rev. Toxicol., 40:531-545, 2010.

Arce, G.T., Gordon , E.B., Cohen, S.M., and Singh, P. Genetic toxicology of folpet and captan. Crit. Rev. Toxicol., 40:546-574, 2010.

Lu, M., Wang, H., Li, X.F., Arnold, L.L., Cohen, S.M., and Le, X.C. Binding of dimethylarsinous acid to cys-13α of rat hemoglobin is responsible for retention of arsenic in rat blood. Chem. Res. Toxicol., 20(1): 27-37, 2007.

For a detailed list of publications, click here.

Samuel M. Cohen, M.D., Ph.D.
Dr. Samuel M. Cohen
Email Address

Mailing Address
985900 Nebraska Medical Center
Omaha, NE 68198-5900

Office Address
MSB 3538

Laboratory Address
DRC2 1016

Phone Numbers
Office: 402-559-6388
Lab: 402-559-6157